Calamos Advisors’s Axsome Therapeutics AXSM Stock Holding History

Calamos Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.6M	Buy	+14,699	New	+$3.19M	0.01%	595
2025 Q1	–	Sell	-12,808	Closed	-$1.08M	–	910
2024 Q4	$1.08M	Buy	+12,808	New	+$1.18M	﹤0.01%	661
2023 Q3	–	Sell	-12,755	Closed	-$917K	–	946
2023 Q2	$917K	Buy	+12,755	New	+$941K	﹤0.01%	715
2020 Q3	–	Sell	-8,446	Closed	-$695K	–	708
2020 Q2	$695K	Buy	+8,446	New	+$650K	﹤0.01%	664

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Calamos Advisors's AXSM Position: Q2 2026 in Review

Calamos Advisors opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 14,699 shares worth $3.6M. The stake represents 0.01% of the portfolio and ranks #595 among its holdings. This is a return to the name: Calamos Advisors previously reported a position in AXSM as recently as Q4 2024.

Calamos Advisors first reported a position in AXSM in Q2 2020 and has held it in 4 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Calamos Advisors held 14,699 shares of Axsome Therapeutics worth $3.6M as of Q2 2026.
Axsome Therapeutics was a new Calamos Advisors position in Q2 2026.
Axsome Therapeutics made up 0.01% of Calamos Advisors's portfolio in Q2 2026, its #595 holding.
Calamos Advisors first reported a position in Axsome Therapeutics in Q2 2020 and has held it in 4 quarters since.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Calamos Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.